Vernakalant (RSD1235) in the Management of Atrial Fibrillation: A Review of Pharmacological properties, Clinical Efficacy and Safety

• Benjamin EJ , WolfPA, D‘AgostinoRB, SilbershatzH, KannelWB, LevyD: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.Circulation, 98(10), 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Kannel WB , WolfPA, BenjaminEJ, LevyD: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.Am. J. Cardiol., 82(8A), N2–N9 (1998).
   PubMed Web of Science ®Google Scholar
• Slavik RS , TisdaleJE, BorzakS: Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.Prog. Cardiovasc. Dis., 44(2), 121–152 (2001).
   PubMed Web of Science ®Google Scholar
• Go AS , HylekEM, PhillipsKAet al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA, 285(18), 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Miyasaka Y , BarnesME, GershBJet al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.Circulation, 114(2), 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Mittal S , SteinKM, MarkowitzSM, IwaiS, GuttigoliA, LermanBB: An update on electrical cardioversion of atrial fibrillation.Card. Electrophysiol. Rev., 7(3), 285–289 (2003).
   PubMedGoogle Scholar
• Gurevitz OT , AmmashNM, MaloufJFet al.: Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter.Am. Heart J., 149(2), 316–321 (2005).
   PubMed Web of Science ®Google Scholar
• Gall NP , MurgatroydFD: Electrical cardioversion for AF-the state of the art.Pacing Clin. Electrophysiol., 30(4), 554–567 (2007).
   PubMed Web of Science ®Google Scholar
• Nerbonne JM , KassRS: Molecular physiology of cardiac repolarization.Physiol. Rev., 85(4), 1205–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Fedida D , OrthPM, ChenJYet al.: The mechanism of atrial antiarrhythmic action of RSD1235.J. Cardiovasc. Electrophysiol., 16(11), 1227–1238 (2005).
   PubMed Web of Science ®Google Scholar
• Fedida D : Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.Expert Opin Investig. Drugs, 16(4), 519–532 (2007).
   PubMed Web of Science ®Google Scholar
• Savelieva I , CammJ: Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.Europace, 10(6), 647–665 (2008).
   PubMed Web of Science ®Google Scholar
• Camm AJ , SavelievaI: New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.J. Interv. Card. Electrophysiol. (2008) (Epub ahead of print).
   Web of Science ®Google Scholar
• Roy D , TalajicM, NattelSet al.: Rhythm control versus rate control for atrial fibrillation and heart failure.N. Engl. J. Med., 358(25), 2667–2677 (2008).
   PubMed Web of Science ®Google Scholar
• Roy D , RoweBH, StiellIGet al.: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.J. Am. Coll. Cardiol., 44(12), 2355–2361 (2004).
   PubMed Web of Science ®Google Scholar
• Eldstrom J , WangZ, XuHet al.: The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.Mol. Pharmacol., 72(6), 1522–1534 (2007).
   PubMed Web of Science ®Google Scholar
• Brendel J , PeukertS: Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.Curr. Med. Chem. Cardiovasc. Hematol. Agents, 1(3), 273–287 (2003).
   PubMedGoogle Scholar
• Vernakalant : RSD 1235, RSD-1235, RSD1235.Drugs RD, 8(4), 259–265 (2007).
   PubMedGoogle Scholar
• Naccarelli GV , WolbretteDL, SamiiSet al.: Vernakalant – a promising therapy for conversion of recent-onset atrial fibrillation.Expert Opin Investig. Drugs, 17(5), 805–810 (2008).
   PubMed Web of Science ®Google Scholar
• Orth PM , HeskethJC, MakCKet al.: RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.Cardiovasc. Res., 70(3), 486–496 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng JW : Vernakalant in the management of atrial fibrillation.Ann. Pharmacother., 42(4), 533–542 (2008).
   PubMed Web of Science ®Google Scholar
• Naccarelli GV , WolbretteDL, SamiiS, BanchsJE, Penny-PetersonE, GonzalezMD: New antiarrhythmic treatment of atrial fibrillation.Expert Rev. Cardiovasc. Ther., 5(4), 707–714 (2007).
   PubMedGoogle Scholar
• Dorian P , PinterA, MangatI, KorleyV, CvitkovicSS, BeatchGN: The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.J. Cardiovasc. Pharmacol., 50(1), 35–40 (2007).
   PubMed Web of Science ®Google Scholar
• Roy D , PrattCM, Torp-PedersenCet al.: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.Circulation, 117(12), 1518–1525 (2008).
   PubMed Web of Science ®Google Scholar
• Kowey PR , RoyD, PrattCMet al.: Efficacy and safety of vernakalant: efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery.Circulation, 116, II636–II637 (2007).
   Web of Science ®Google Scholar
• Roy D , PrattC, CammAJ, GrantS, KittTM, MangalB: RSD1235 effectively converts acute atrial fibrillation to sinus rhythm independent of background use of oral rateor rhythm-control medications.Ann. Emerg. Med., 48 (Suppl.), S46 (2006) (Abstract 148).
   Web of Science ®Google Scholar

Websites

• Astellas Pharma US, Inc., Kynapid, vernakalant hydrochloride injection. NDA 22–034. www.fda.gov/ohrms/dockets/ac/07/briefing/2007–4327b1–01-astellas-backgrounder.pdf.
   Google Scholar
• Cardiome Pharma Corp. Vernakalant (oral). www.cardiome.com/VernakalantOral.php
   Google Scholar
• Cardiome Pharma Corp. Vernakalant. http://cardiome.com/wordpress/?p=443
   Google Scholar
• Cardiome Pharma Corp. Vernakalant (intravenous). www.cardiome.com/VernakalantIntravenous.php
   Google Scholar
• FDA advisory committee recommends approval of Kynapid for acute atrial fibrillation. www.astellas.us/press_room/docs/071211%20-%20FDA%20Panel%20Vote%20-%20FINAL.pdf
   Google Scholar